The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 18, 2017
Filed:
Nov. 09, 2011
Alice Ravn Madsen, Roedovre, DK;
Birgit Wieczorek, Koebenhavn N, DK;
Jacob Kofoed, Vaerloese, DK;
Jesper Lau, Farum, DK;
Jane Spetzler, Broenshoej, DK;
Janos Tibor Kodra, Koebenhavn Oe, DK;
Lars Linderoth, Alleroed, DK;
Patrick William Garibay, Holte, DK;
Per Sauerberg, Farum, DK;
Thomas Kruse, Herlev, DK;
Alice Ravn Madsen, Roedovre, DK;
Birgit Wieczorek, Koebenhavn N, DK;
Jacob Kofoed, Vaerloese, DK;
Jesper Lau, Farum, DK;
Jane Spetzler, Broenshoej, DK;
Janos Tibor Kodra, Koebenhavn Oe, DK;
Lars Linderoth, Alleroed, DK;
Patrick William Garibay, Holte, DK;
Per Sauerberg, Farum, DK;
Thomas Kruse, Herlev, DK;
Novo Nordisk A/S, Bagsvaerd, DK;
Abstract
The invention relates to a derivative of a GLP-1 analog, which analog comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3:HOOC—(CH)—CO—*  Chem. 1:HOOC—CH—O—(CH)—CO—*  Chem. 2:R—CH—(CH)—CO—*,  Chem. 3: The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.